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Abstract
Two genetic variants in strong linkage disequilibrium (rs9536314 and rs9527025) in the
Klotho (KL) gene, encoding a transmembrane protein, implicated in longevity and
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Investigating the role of Klotho heterozygosity on Alzheimer disease risk

associated with brain resilience during normal aging, were recently shown to be associated
with Alzheimer disease (AD) risk in cognitively normal participants who are APOE ε4 carriers. Specifically, the participants heterozygous for this variant (KL-SVHET+) showed lower
risk of developing AD. Furthermore, a neuroprotective effect of KL-VSHET+ has been suggested against amyloid burden for cognitively normal participants, potentially mediated via
the regulation of redox pathways. However, inconsistent associations and a smaller sample
size of existing studies pose significant hurdles in drawing definitive conclusions. Here, we
performed a well-powered association analysis between KL-VSHET+ and five different AD
endophenotypes; brain amyloidosis measured by positron emission tomography (PET)
scans (n = 5,541) or cerebrospinal fluid Aβ42 levels (CSF; n = 5,093), as well as biomarkers
associated with tau pathology: the CSF Tau (n = 5,127), phosphorylated Tau (pTau181; n =
4,778) and inflammation: CSF soluble triggering receptor expressed on myeloid cells 2
(sTREM2; n = 2,123) levels. Our results found nominally significant associations of KLVSHET+ status with biomarkers for brain amyloidosis (e.g., CSF Aβ positivity; odds ratio [OR]
= 0.67 [95% CI, 0.55–0.78], β = 0.72, p = 0.007) and tau pathology (e.g., biomarker positivity
for CSF Tau; OR = 0.39 [95% CI, 0.19–0.77], β = -0.94, p = 0.007, and pTau; OR = 0.50
[95% CI, 0.27–0.96], β = -0.68, p = 0.04) in cognitively normal participants, 60–80 years old,
who are APOE e4-carriers. Our work supports previous findings, suggesting that the KLVSHET+ on an APOE ε4 genotype background may modulate Aβ and tau pathology, thereby
lowering the intensity of neurodegeneration and incidence of cognitive decline in older controls susceptible to AD.

Introduction
Alzheimer disease (AD), the most common form of dementia, affects about 30% of those aged
over 85 years [1]. AD is classified as a neurodegenerative disease, affecting brain integrity and
function, eventually resulting in progressive deterioration of cognitive capabilities [2]. Besides
aging, a strong genetic risk factor for developing AD is the epsilon 4 allele of the apolipoprotein E gene (APOE ε4) [3, 4]. As such, participants carrying one or two APOE ε4 alleles are significantly overrepresented among persons diagnosed with AD, in comparison to non-carriers
[5, 6]. This particular genetic variant has been shown to be associated with cognitive decline
[7] and reduced mean age at onset even within families with late onset AD [8]. Further, APOE
ε4 homozygosity among cognitively normal participants is associated with earlier and more
abundant Aβ deposition [9–12], earlier pre-clinical memory decline [13], and an increased
incidence of conversion to dementia [9], in comparison to APOE ε4 heterozygotes and noncarriers. These observations suggest that APOE ε4 influences the very core of AD pathophysiology, in large part due to its key role in fostering cerebral Aβ pathology. Therefore,
identifying genetic factors that interact with APOE ε4 genotype to reduce Aβ burden and,
eventually, a participant’s risk for developing AD, may inspire novel strategies for preventing
or halting the progression of AD and reveal novel targets for effective therapeutic
interventions.
One such genetic factor that has been recently reported and showed a protective effect
among cognitively normal APOE ε4 carriers is polymorphism on Klotho (KL) gene [6, 14, 15].
KL is a transmembrane protein that is cleaved by α- and β-secretases and shed into CSF and
plasma, where it acts as a signaling molecule and longevity factor [16, 17] that promotes
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neuronal functions and brain resilience during aging [18–20]. In humans, two KL gene variants (rs9536314 for p.F352V and rs9527025 for p.C370S) exist in strong linkage disequilibrium
and segregate together as a functional haplotype called KL-VS. Interestingly, heterozygosity
for the KL-VS haplotype (KL-VSHET+) has been associated with higher serum concentrations
of KL [18, 21] which, in turn, has been reported to promote healthy brain aging and protect
synaptic functions in comparison to participants who carry two copies of the KL-VS haplotype
(KL-VSHET-) [20, 22]. Even though KL-VSHET+ is associated with better cognitive health and
longevity among those aging normally, there exist no clear indication of its involvement in
protection against aging-associated neurodegenerative disorders, such as AD.
Identification of genetic risk factors for AD based on clinical diagnosis poses several challenges. A clinical diagnosis of AD relies in part on evidence of cognitive decline using standard
cognitive tests that might be influenced by factors unrelated to disease (e.g., anxiety, education,
and general test-taking ability of the participant [23]). In addition, other salient factors that
can play an important role include variability in the cognitive measures [24, 25], over-reliance
on normative cut-off scores to diagnose dementia, and practice effect [24, 26]. A complementary approach to classical case-control studies involves the use of more robust and stable measures (endophenotypes) that support a diagnosis of AD, such as cerebrospinal fluid (CSF)
biomarkers and Aβ burden assessed by positron emission tomography (PET). This approach
can increase statistical power to identify AD genetic risk factors, discover novel associations,
and understand their impact on the brain [27]. For example, by using brain endophenotypes,
researchers have identified novel protective genetic variants in TMEM106B and MS4A genes,
associated with neuroprotection (high neuronal proportion) in AD [28], and increased CSF
soluble triggering receptor expressed on myeloid cells 2 (sTREM2) concentrations with
reduced AD risk, respectively [29].
In the spectrum of AD pathology and different genetic factors that exert a protective effect
in the context of disease onset and/or progression, KL-VS appears to be a compelling candidate due to its implication in promoting longevity and cognitive resilience during aging [18,
20, 22]. Interestingly, two recent studies evaluating the protective effect of KL-VSHET+ against
AD pathology in cognitively normal participants [15, 30] provided contradictory evidence.
The first study [15] focused on 309 late-middle-aged adults (mean age 61 years) and found
KL-VSHET+ to be associated with reduced Aβ aggregation, suggesting its protective effect
against APOE ε4-linked pathways to disease onset in AD. The second study [30] analyzed data
from 581 adults (mean age 71 years) and found no significant associations between KL-VSHET
+
and cognitive decline, independent of the APOE ε4 genotype, suggesting no modifying effect
of KL-VSHET+ on Aβ aggregation and APOE ε4-driven cognitive decline in preclinical AD.
Furthermore, a study assessing the association between Klotho KL-VS haplotype and cognition using data from the population-based Heinz Nixdorf Recall Study in 1812 subjects (55–87
years) suggested a slightly lower cognitive performance in KL-VSHET+ subjects [31]. However,
a recent large-scale meta-analysis [6] that focused on cognitively normal participants in the
age range of 60–80 years revealed a 30% reduction in AD risk for participants who are APOE
ε4 carriers and KL-VSHET+. They also observed a significant associations between KL-VSHET+
and higher Aβ42 in CSF (p = 0.03) and between KL-VSHET+ and lower Aβ on PET scans
(p = 0.04), modulated by APOE ε4 status. Focusing on tau pathology, a recent study showed
KL-VSHET+ to be associated with both lower levels and slower rate of change in amyloidrelated increase of tau-PET accumulation in asymptomatic and symptomatic elderly participants, supporting a protective effect of KL-VSHET+ on the primary AD pathologies [32]. Due
to contradictory outcomes from the existing reports and their relatively small sample sizes, we
performed a systematic evaluation of association between KL-VSHET+ and multiple well-established AD endophenotypes to evaluate whether it has a protective effect on AD pathology in
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asymptomatic elderly participants. Here, we have performed a well-powered association analysis between KL-VSHET+ and five different AD endophenotypes: Aβ assessed by PET scans
(n = 5,541) and CSF (n = 5,093), as well as the CSF Tau (n = 5,127), phosphorylated Tau
(pTau181; n = 4,778) and sTREM2 (n = 2,123). In line with previous studies, we performed
APOE ε4- and age-stratified (60–80 years) analyses to determine if there is any association
between KL-VSHET+ and Aβ aggregation that is modulated by APOE ε4 status. In addition, we
also evaluated if there is any association between KL-VSHET+ and other AD endophenotypes
that include Tau, pTau, and sTREM2 measured by CSF. Briefly, in the case of APOE ε4-carriers, we found significant associations between KL-VSHET+ and biomarkers for brain amyloidosis (CSF Aβ42; p = 0.007) and tau pathology (CSF Tau; p = 0.007, and pTau; p = 0.04). As
evident from the observed P-values, the detected associations are nominally significant and
would likely fail multiple test correction, indicating the need for validating these findings in
studies with even larger sample sizes before drawing definitive conclusions. Nevertheless, these
findings suggest that KL-VSHET+ exerts an APOE ε4-genotype dependent protective effect on
CSF Tau and pTau concentrations and on subsequent cognitive decline in older cognitively
normal participants susceptible to AD.

Methods
Study samples and phenotype processing
Written consent was obtained for all participants. This study was approved the Washington
University Human study committee. IRB approval #: 201109148.
For this study, we collected data from 17 different AD-related cohorts. Participants were
enrolled in the Memory and Aging Project (MAP) at the Knight Alzheimer’s Disease Research
Center (Knight-ADRC), Alzheimer’s Disease Neuroimaging Initiative (ADNI, adni.loni.usc.
edu), BIOCARD, the Dominantly Inherited Alzheimer Network (DIAN), HB, Hospital Sant
Pau (Lleo), London, MOLI, Pau, Mayo Clinic (Mayo), SWEDEN, UPENN, UW, Parkinson’s
Progression Markers Initiative (PPMI), Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4), and ADNI Department of Defense (ADNIDOD) studies. Total sample size
was 9,526 (S1 Table in S2 File). Collection of genotype data, PET image processing, and CSF
data processing for each cohort are described in detail in the respective studies [10, 11, 28, 29,
33, 34]. We analyzed the association between KL-VSHET+ and five different AD endophenotypes (Table 1) that served as biomarkers for brain amyloidosis (Aβ pathology assessed by
amyloid-PET [n = 5,541] and Aβ42 measured from CSF [n = 5,093]), tau pathology (Tau
[n = 5,127] and pTau181 [n = 4,778] from CSF), and inflammation (sTREM2 levels from CSF
[n = 2,123]). A schematic overview of the analyses conducted and the datasets used is provided
in Fig 1.
Briefly, participants were diagnosed as cognitively normal (controls) or AD (cases), based
on the clinical dementia rating (CDR) that was available for 88% of the total dataset. The CDR
is a five-point scaling system that describes the overall dementia severity for each participant
(no dementia = 0, very mild = 0.5, mild = 1, moderate = 2, and severe = 3). Participants with
CDR = 0 were categorized as controls, and those with CDR > 0 were defined as cases. Any participant who was missing information about age, sex, KL-VSHET+, APOE ε4 genotype, or
genetic principal components (PCs) was excluded from the analysis. Following this rationale,
we considered 3,725 cognitively normal participants assessed by amyloid-PET and 1,030 cognitive normal participants measured by CSF (Aβ42, Tau, and pTau) and 639 participants with
CSF sTREM2 levels. Similarly, the number of clinically defined AD participants assessed from
amyloid-PET, CSF Aβ42, Tau, pTau, and sTREM2 were 1,090, 2,424, 2,443, 2,297, and 1,074,
respectively.
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Table 1. Demographics of analyzed Alzheimer’s disease (AD) endophenotypes.
Total

Amyloid-PET

Aβ42

Tau

pTau181

sTREM2

Sample size

9,526

5,541

5,093

5,127

4,778

2,123

Female (%)

51.86

54.54

49.30

49.19

48.68

50.31

68.93 (11.13)

69.53 (10.73)

67.04 (13.27)

67.15 (13.30)

66.93 (13.43)

68.17 (12.13)

Age, mean (SD)
APOE ε4+ (%)

39.03

37.39

40.74

41.08

39.47

42.11

0.028 (0.02)

0.045 (1.03)

-0.0018 (1)

0.027 (1)

0.02 (1)

0.05 (0.98)

Klotho-VSHET+ (%)

25.76

25.99

25.31

25.16

25.09

25.20

Cases

3,109

1,090

2,424

2,443

2,297

1,074

Controls

5,286

4,117

1,584

1,589

1,582

879

Biomarker, mean (SD)

Demographics of participants at the time of amyloid PET imaging and CSF sampling. This table summarizes basic demographic information of participants included in
the analysis. For each modality, we report percentage of females, mean age of the participants and standard deviation (SD) in the age, percentage of APOE ε4-carriers
(APOE ε4+) participants, mean value of the endophenotypic biomarker and its SD, percentage of KL-VS heterozygous (KL-VSHET+) participants, and number of cases
and controls. Samples with missing case/controls status were also considered in the ‘all participants’ analysis. To normalize endophenotypes across different cohorts, we
converted different amyloid imaging measures (e.g., Centiloid, PiB, and AV45) into log-normalized z-score using “scale” function in base R. Phenotype from each
cohort was normalized individually to account for within cohort variation. These AD endophenotypes are used for checking their association with KL-VSHET+.
Abbreviations: PET, positron emission tomography; Aβ, β-amyloid; pTau, phosphorylated tau; soluble triggering receptor expressed on myeloid cells 2, sTREM2; sd,
standard deviation; KL-VS, Klotho-VS; Het+, heterozygosity.
https://doi.org/10.1371/journal.pone.0267298.t001

For each cohort, amyloid PET images were normalized to their reference cerebellar regions
to obtain standardized uptake value ratios (SUVR) in a composite of cortical brain areas. The
normalized z-scores were calculated for each endophenotype using the mean and standard
deviation (SD) units across each cohort and applied to the entire endophenotype. These normalized z-scores were used for dichotomizing each endophenotype into biomarker positive

Fig 1. Schematic overview of datasets and performed analysis. Number of participants in each modality were stratified into three categories: 1) All of
the participants; 2) Age: 60–80, participants aged 60 to 80 years; 3) CN: 60–80, cognitively normal participants aged 60 to 80 years. Association between
KL-VSHET and endophenotypes were assessed using generalized linear mixed (logistic regression) model for dichotomized phenotype. Age, sex, and
first three genetic PCs were used as covariates in an APOE ε4-stratified analysis. Abbreviations: PET, positron emission tomography; N, number of;
CSF, cerebrospinal fluid; Aβ, β-amyloid; pTau, phosphorylated tau181; soluble triggering receptor expressed on myeloid cells 2, sTREM2; CN,
cognitively normal; KL, Klotho; Het, heterozygous; PC, principal component.
https://doi.org/10.1371/journal.pone.0267298.g001
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Fig 2. Cutoffs for dichotomizing different AD endophenotypes across MAP and ADNI cohorts. A density plot defining the dichotomization cutoffs
for Aβ assessed by PET scan and Aβ42 from CSF in MAP and ADNI cohorts. The distribution of z-score for cases and controls is shown by red and
blue dotted lines, respectively. The cut-off point where both these distributions overlap was selected as the dichotomization threshold for each
endophenotype. The dichotomization was performed on normalized z-scores for each endophenotype. However, the corresponding raw score for each
dichotomization threshold is also labelled in the plot. Abbreviations: Aβ, β-amyloid; PET, positron emission tomography; MAP, Memory and Aging
Project; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CSF; Cerebrospinal fluid.
https://doi.org/10.1371/journal.pone.0267298.g002

(case) and negative (control), as previously described [11]. Briefly, defining biomarker positivity and negativity requires the selection of a cut-point. We and others [11, 35, 36] have demonstrated that it is possible to use Gaussian mixture model (GMM) to statistically infer that cutoff. We overlapped the distributions of quantitative z-scores from cases and controls for each
endophenotype and employed a GMM that relies on hierarchical model-based agglomerative
clustering to get votes for defining a cut-point for dichotomization. We used Mclust function
from “mclust” R package (version 5.4.6) for dichotomizing all quantitative endophenotypes
separately. The empirical dichotomization cutoffs obtained using this approach appeared consistent with existing literature. For instance, our model suggested the cut-point of 527 pg/mL
for Aβ42 from CSF in MAP cohort which is between 500 pg/mL [37] to 518 ng/l [35] depending on the study. A density plot defining the dichotomization cutoffs for Aβ assessed by PET
scan and Aβ42 from CSF in MAP and ADNI cohorts is shown in Fig 2. Further details about
the empirical cutoffs derived from z-scores and their corresponding raw values are provided in
S2 Table in S2 File. The dichotomized (biomarker positive/negative) endophenotypic status
was used as a response variable to assess its association with Klotho heterozygosity.

Genotyping, quality checks, imputation, and population structure
We applied stringent quality control (QC) steps to process the genotyping array and sequencing data. We used the threshold of 98% for removing single nucleotide polymorphisms (SNPs)
and participants with low call rate. Autosomal SNPs that were not in the Hardy-Weinberg
equilibrium (P < 1×10−6) were also removed. Duplication and relatedness of participants were
estimated from identity-by-descent (IBD) analysis carried out in Plink version 1.9 [38]. In case
of related participants (Pihat �0.25), the samples from MAP or with a higher number of variants that passed the QC were prioritized. For phasing and imputation, we used The 1000
Genomes Project Phase 3 data (October 2014), SHAPEIT v2.r837 [39], and IMPUTE2 v2.3.2
[40]. We used imputed probability score < 0.90 and �0.90 as thresholds for missing and fully
observed participant genotypes, respectively. Genotyped and imputed variants with
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MAF < 0.02 or IMPUTE2 information score < 0.30 were discarded. Principle component
analysis (PCA) was performed on the genotype data to obtain genetic PCs that capture population substructure (S2 Fig in S1 File). To obtain the largest and most homogeneous pool of population, only European participants were considered (S3 Fig in S1 File) for the subsequent
statistical analyses.

Statistical analyses
Statistical analyses and data visualization were performed in Plink version 1.9 [38] and R version 3.5.2 [41]. We performed association analyses of KL-VSHET+ status with different AD
endophenotypes from PET scan (Aβ) and CSF (Aβ42, Tau, pTau, and TREM2). The associations between the biomarker positivity and KL-VSHET+ were tested using logistic regression
model. The implementation of regression model from the base R [41] “stats” package was used
for the evaluation of association and the outcomes measurements were adjusted for sex, age,
and first three genetic PCs. For the Aβ levels measured by PET scan, we considered the age at
scan and in the case CSF biomarker levels, age at lumbar puncture. Furthermore, associations
were evaluated across three different strata: (1) all participants (AD and controls); (2) those
aged 60 to 80 years (AD and controls); and (3) only cognitively normal participants aged 60 to
80 years. All association analyses were stratified by APOE ε4 status: APOE ε4 carriers (APOE24, 34, and 44) and APOE ε4 non-carriers (APOE- 22, 32, and 33). Associations were deemed
significant at a threshold of p < 0.05.

Results
The primary aim of this study was to determine whether there is a significant association
between KL-VSHET+ and AD endophenotypes in cognitively normal participants who are
APOE ε4-carriers. In addition, we also assessed the KL-VS effects in participants with AD
dementia. To accomplish this goal, we analyzed genetic data and five different AD endophenotypes from 9,526 participants obtained through 17 different AD-related cohorts. In line with
existing studies [6, 15], our findings validate the protective effect of KL-VSHET+ against AD in
cognitively normal participants who are APOE ε4 carriers.

Association between KL-VSHET+ status and brain amyloidosis measured by
PET scan and CSF
We evaluated the association of KL-VSHET+ status with Aβ pathology as measured by amyloidPET and CSF Aβ42 for 5,541 and 5,093 participants, respectively (Table 1). Although associations were evaluated for three different age ranges (S3 Table in S2 File), our main focus was
cognitively normal participants who are 60 to 80 years old (Table 2). We focused on this age
range to be consistent with existing studies that report a pronounced effect of APOE ε4 positivity on AD dementia risk between age 60 to 80 years in comparison to older participants (�80
years) [6, 42]. For Aβ levels measured by PET, we observed that KL-VSHET+ status was more
prevalent in Aβ biomarker negative participants in comparison to the positive ones, but there
was no significant association within any age group or APOE ε4 strata (S3 Table in S2 File).
On the other hand, we found a significant association between KL-VSHET+ status and CSF Aβ
biomarker positivity in cognitively normal APOE ε4-carrier participants who are 60 to 80
years old (Table 2; OR = 0.67 [95% CI, 0.55–0.78], β = 0.72, p = 0.007). We also observed a significant association for APOE ε4 non-carriers; however, the effect size and the strength of the
association was lower in this group (OR = 0.61 [95% CI, 0.51–0.70], β = 0.46, p = 0.03) than
the APOE ε4-carriers (Table 2). Taken together, we were able to replicate the previously
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Table 2. Genetic association of KL-VSHET+ with AD endophenotypes in cognitively normal participants aged 60–80 years, stratified by APOE ε4 status.
Modality

Group

CN participants

Odds ratio

Estimate

P value

(KL-VSHET+ %)
Amyloid PET

APOE4+

1328 (27.5)

0.94

-0.07

0.61

APOE4-

2397 (26.5)

0.99

-0.01

0.90

APOE4+

308 (26.3)

0.67

0.72

0.007

APOE4-

722 (26.3)

0.61

0.46

0.03

APOE4+

308 (26.9)

0.39

-0.94

0.007

APOE4-

722 (26.5)

0.85

-0.16

0.49

pTau

APOE4+

308 (26.9)

0.50

-0.68

0.04

APOE4-

722 (26.3)

0.89

-0.11

0.61

sTREM2

APOE4+

199 (31.2)

1.08

0.08

0.80

APOE4-

440 (25.2)

1.20

0.18

0.43

Aβ42
Tau

Association between KL-VSHET+ and different dichotomized AD endophenotypes were assessed using logistic regression model. We used dichotomized endophenotype
as the response variable, whereas, age, sex, and first three genetic PCs were used as covariates in an APOE4-stratified analysis. Significant associations are represented by
bold P-values. Abbreviations: KL-VSHET+, Klotho-VS heterozygous; CN, cognitively normal; AD, Alzheimer’s disease; Std. Error, Standard error; %, percentage; Aβ, βamyloid; pTau, phosphorylated tau181; soluble triggering receptor expressed on myeloid cells 2, sTREM2.
https://doi.org/10.1371/journal.pone.0267298.t002

reported associative findings [6, 42] between increased Aβ42 CSF levels and KL-VSHET+ in a
larger sample group (S1 Fig in S1 File).

APOE ε4-related alteration in tau pathology varies by KL-VSHET+ status
Similar to Aβ association analyses, we also determined if there was an age- and APOE
ε4-dependent association of KL-VSHET+ status with dichotomized CSF Tau and pTau biomarker positivity. In the age range of 60 to 80 years, we observed significant association
between KL-VSHET+ status and CSF Tau (OR = 0.39 [95% CI, 0.20–0.77], p = 0.007), and pTau
(OR = 0.50 [95% CI, 0.27–0.96], p = 0.04) levels in elderly (60–80 years) cognitively normal
APOE ε4-carrier participants (Table 2). In both cases, the KL-VSHET+ was associated with biomarker negative status (e.g., lower CSF Tau or pTau levels which are associated with lower AD
risk (β = -0.94 and -0.68 for Tau and pTau, respectively). Regarding the effect size, we observed
an almost 6-fold decrease for both Tau and pTau levels in APOE ε4-carriers as compared to
the non-carriers, suggestive of a more pronounced protective effect for participants carrying
one copy of KL-VS haplotype. As expected, a consistent negative association was observed for
both modalities when effect sizes were represented in the form of a Forest plot (Fig 3). While
we observed similar trends in the effect of KL-VSHET+ on tau pathology biomarker negativity
for cognitively normal participants who are APOE ε4 non-carriers (β = -0.16 and -0.11 for Tau
and pTau, respectively), the association was not deemed significant (p = 0.49 and 0.61 for Tau
and pTau, respectively).
To further elucidate the link between APOE ε4 and KL-VSHET+, we performed the association analysis including an interaction effect for the presence or absence of APOE ε4 and the
status of each biomarker (positive or negative). Results did not showed any significant association across any endophenotype (S4 Table in S2 File), emphasizing the APOE ε4-dependent
association of KL-VSHET+ and different AD endophenotypes. In addition, we also assessed
associations between APOE ε4 and AD pathologies in the group with 0 and 2 copies of KL-VS
haplotype (KL-VSHET-). We observed no significant association across any AD endophenotypes (S5 Table in S2 File), confirming the existing hypothesis that suggests the neuroprotective effect of KL heterozygosity (KL-VSHET+) but not the homozygosity (KL-VSHET-) [20, 22].
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Fig 3. Forest plot of odds ratio (OR) for KL-VSHET+ association with dichotomized AD endophenotypes in 60–80 year cognitively normal
participants, stratified by APOE ε4 status. A significant association was detected between KL-VSHET+ and dichotomized Aβ, Tau, and pTau CSF
levels. In case of Aβ, the associations were deemed significant across both APOE ε4 strata, whereas for Tau and pTau, associations were observed only
in APOE ε4-carriers, representing an exclusive protective effect of KL-VSHET+ for the cognitively normal participants aged 60 to 80 years and carrying
APOE ε4. Abbreviations: APOE4+, Apolipoprotein E4 positive; APOE4-, Apolipoprotein E4 negative; PET, positron emission tomography; Aβ, βamyloid; pTau, phosphorylated tau181; soluble triggering receptor expressed on myeloid cells 2, sTREM2.
https://doi.org/10.1371/journal.pone.0267298.g003

Direct effect of KL-VSHET+ status on inflammation-specific biomarker
For sTREM2 CSF levels, we did not observe any significant association between this inflammation biomarker and KL-VSHET+ status across any participant stratification, regardless of the
age group and APOE ε4 status. Nevertheless, for cognitively normal participants aged 60 to 80
years, we observed that KL-VSHET+ status is associated with increased sTREM2 CSF levels,
which represents the positivity of inflammation-specific biomarker, but association was not
deemed significant in APOE ε4-carriers (OR = 1.08 [95% CI, 0.58–2], β = 0.08, p = 0.80) as
well as non-carriers (OR = 1.20 [95% CI, 0.77–1.86], β = 0.18, p = 0.43).

Sensitivity analysis result: Robustness of the associations between
KL-VSHET+ status and brain amyloidosis to the APOE ε4 status, age, and
sex
In order to estimate whether the associations between KL-VSHET+ and amyloidosis were confounded by uneven sample size of APOE ε4-carriers and non-carriers as well as by differences
in the sex and age of the participant groups, the association analyses were repeated with equal
numbers of APOE ε4-carriers (N = 308) and non-carriers (N = 308) matched for age and sex.
As in the full-sample analyses for cognitively normal participants aged 60 to 80, these smaller,
balanced analyses revealed that KL-VSHET+ was consistently associated with CSF Aβ biomarker positivity among APOE ε4-carriers (OR = 0.68 [95% CI, 0.56–0.78], β = 0.75,
p = 0.005; S6 Table in S2 File) and among APOE ε4 non-carriers (OR = 0.69 [95% CI, 0.51–
0.79], β = 0.70, p = 0.034). Likewise, similar trends were observed between the full-sample and
smaller, balanced analyses for amyloid imaging, CSF Tau, pTau181, and sTREM2 (S6 Table in

PLOS ONE | https://doi.org/10.1371/journal.pone.0267298 May 26, 2022

9 / 16

PLOS ONE

Investigating the role of Klotho heterozygosity on Alzheimer disease risk

S2 File). In these corrections for class imbalance of APOE ε4-carriers and non-carriers, as well
as for males and females of same age, the direction of effect remains the same for each endophenotype, and the strength of association becomes more profound (lower p-values). Taken
together, these results suggest that observed associations between KL heterozygous cognitively
normal participants and different AD endophenotypes (e.g. tau and pTau) are independent of
the distribution of APOE ε4 carriage status, age, and sex of participants.

Cognitively normal participants (aged 60 to 80) drive association between
KL-VSHET + status and AD endophenotypes
We also conducted APOE ε4-stratified association analyses between KL-VSHET+ status and biomarkers for brain amyloidosis (Aβ from PET and CSF), tau-related pathology (CSF Tau and
pTau), and inflammation (CSF sTREM2) for all participants, regardless of their age and casecontrol status. In these larger inclusive analyses, no significant association was observed
between KL-VSHET+ and any of the five endophenotypes (S3 Table in S2 File). Similarly, we also
performed the same analyses but restricting to participants between 60 and 80 years of age,
regardless of their case-control status; even in that case, no significant association was detected
across any endophenotype (S3 Table in S2 File). Only when participants were restricted to the
age range 60–80 and cognitive normalcy were significant association detected between
KL-VSHET+ status and CSF Aβ, Tau, and pTau levels (S3 Table in S2 File). Notably, these findings suggest that the nearly-significant associations observed in the more inclusive analyses (e.g.
for Aβ42) were mainly driven by the cognitively normal participants who are 60 to 80 years old.

Discussion
The role of Klotho protein as a longevity factor is widely recognized [16, 17]. There has been
an increasing amount of evidence supporting the relationship between KL-VSHET+ and preserved brain integrity and cognitive performance during normal aging [18–20]. In this study,
we examined the association of KL-VSHET+ status with five different AD-related endophenotypes that serve as biomarkers for brain amyloidosis (Aβ levels measured from CSF and amyloid PET), tau pathology (CSF Tau and pTau), and inflammation (sTREM2). To our
knowledge, we have analyzed the largest sample size of AD endophenotypic data for evaluating
its association with KL-VSHET+; this approach is instrumental to discern the potential protective effect of this heterozygous genetic variant for AD in cognitively normal APOE ε4-carriers.
Our results showed that KL-VSHET+ status was associated with CSF Aβ42, Tau and pTau biomarker negativity in participants who are cognitively normal APOE ε4-carriers within an age
range of 60 to 80 years. This finding suggests that KL-VSHET+ status reduces the risk of subsequent AD dementia among APOE ε4-carriers by lowering the AD pathology burden [6, 42].
We were able to replicate the findings by Belloy et al. [6]; that is, KL-VSHET+ status was significantly associated with increased CSF Aβ42 levels (Aβ biomarker positivity) for cognitively
normal participants aged 60 to 80 years who are APOE ε4-carriers (OR = 0.67 [95% CI, 0.55–
0.78], β = 0.72, p = 0.007). Further, our analyses also found this association to be significant
among APOE ε4 non-carriers (OR = 0.61 [95% CI, 0.51–0.70], β = 0.46, p = 0.03), with similar
(overlapping 95% CI) effect sizes (Table 2). Although no significant association was observed
with amyloid PET, the detected trend towards a negative association suggests that KL-VSHET+
may protect against AD by reducing deposits of Aβ that are capable of binding amyloid PET
tracers. Consistently, studies have shown a very high concordance between CSF Aβ42 and
amyloid PET [43], but with a proportion of individuals with discordant results (CSF+/PET-);
such individuals may represent the earliest stages of AD neuropathologic change, when low
CSF Aβ levels appear to coincide with early amyloid deposition, but amyloid deposits have not
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yet accrued sufficiently to reach threshold for amyloid-PET tracer binding, and neurodegeneration has not yet begun [44, 45]. In support of this interpretation, a previous study investigating longitudinal differences in cognition between participants without dementia with different
CSF and PET profiles found no memory decline in concordant-negative (CSF−/PET−) and
discordant (CSF+/PET−) groups, in contrast to the concordant-positive (CSF+/PET+) group
that deteriorated over time [46]. Furthermore, Palmqvist et al. [44] reported similar results,
when they analyzed 437 non-demented participants from ADNI whose results from amyloid
PET scans and CSF Aβ measurements showed that CSF Aβ levels become abnormal in the earliest stages of AD, before amyloid PET and before neurodegeneration starts.
We also investigated whether KL-VSHET+ status is significantly associated with Tau and
pTau levels in CSF. We found that KL-VSHET+ status was significantly associated with
decreased levels of CSF Tau (OR = 0.39 [95% CI, 0.20–0.77], β = -0.94, p = 0.007) and pTau
(OR = 0.50 [95% CI, 0.27–0.96], β = -0.68, p = 0.04) i.e., CSF Tau and pTau biomarker negativity, in participants who are APOE ε4-carriers and 60 to 80 years old. Interestingly, APOE ε4
non-carriers showed similar negative trends, but the associations were not significant for Tau
(OR = 0.85 [95% CI, 0.54–1.35], β = -0.16, p = 0.49) or pTau (OR = 0.89 [95% CI, 0.57–1.39], β
= -0.11, p = 0.61). This indicates that KL-VSHET+ status interaction with pathological aspects
of AD are more profound among APOE ε4-carriers, such as Aβ and Tau accumulation during
the pre-clinical phase of the disease [47, 48]. Although we did not find a protective effect of
KL-VSHET+ in individuals with AD dementia, a recent study reported that KL-VSHET+ attenuated the association between higher amyloid PET and higher increases in tau PET accumulation [32]. Reasons for the discrepancy could be that here we did not investigate interaction
effects of KL-VSHET+ and amyloid on tau pathology, and second, we did not investigate tau
PET, which assesses fibrillar tau deposits, whereas CSF p-tau181 appears to represent one or
more earlier phenomena that do not closely correlate with neurofibrillary tangle burden.
Indeed, previous studies have also reported a significant association between KL-VS heterozygosity and reduced tau accumulation and lower memory impairment in elderly humans at risk
of AD dementia [32, 49]. However, in a mouse model of AD that was used to examine the neuroprotective effects of Klotho protein against neuronal damage associated with oxidative stress
and neurodegeneration, no changes in Tau phosphorylation were observed in the presence of
Klotho [50]. Unlike Tau and pTau association with KL-VSHET+ status, we observed a positive
association with CSF levels of sTREM2 (inflammation biomarker). The observed increase in
CSF sTREM2 levels was not significantly associated with KL-VSHET+ status for either APOE
ε4-carriers (OR = 1.08 [95% CI, 0.59–2], β = 0.08, p = 0.80) or non-carriers (OR = 1.20 [95%
CI, 0.77–1.86], β = 0.18, p = 0.43). Interestingly, recent studies [29, 34, 51, 52] have shown that
higher sTREM2 levels are associated with lower AD risk and slower progression. Therefore,
the observed positive association suggests that the protective effect of the KL-VSHET+ might be
mediated by higher CSF sTREM2 levels. However, this hypothesis will need to be validated in
studies with larger sample size for CSF sTREM2 levels.
Taken together, the observed significant associations between KL-VSHET+ status and biomarkers for brain amyloidosis (CSF Aβ positivity) and tau pathology (CSF Tau and pTau negativity) are suggestive of neuroprotective effect of KL-VSHET+ against age-related biomarker,
biomolecular, and cognitive alterations that confer risk for AD. Our results further strengthen
the findings of a recent meta-analysis including 25 independent studies, showing that APOE
ε4-carriers who were also KL-VSHET+, were at a reduced risk for the combined outcome of
conversion to mild cognitive impairment (MCI) or AD [6]. Besides, several other studies that
evaluated the association of KL-VSHET+ status with different cognitive measures in control
participants did not consider interactions with APOE ε4 but did observe protective associations that were more pronounced closer to 80 years of age [18, 53, 54].
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Notably, we assessed the associations between KL-VSHET+ status and AD endophenotypes
across three age strata: all of the participants (AD and controls); only those aged 60 to 80 years
(AD and controls); and only cognitively normal participants aged 60 to 80 years (S3 Table in
S2 File). Owing to a higher genetic risk for AD attributable to APOE ε4 in individuals who are
60 to 80 years old [55–57] and an existing study that hypothesized protective association of
KL-VSHET+ status to be strongest in APOE ε4 carriers who are 60 to 80 years old [6], the a priori focus of the current study was also at this particular age range. Although we observed similar associative trends most of the time, it was interesting to see how the effects became
apparent when restricting analyses to the cognitively normal participants in the age range of
60 to 80 years. In all of the cases, no significant associations were observed between KL-VSHET
+
status and AD endophenotypes while considering all of the AD and cognitively normal participants, or all of the AD and cognitively normal participants within age range of 60–80. However, pronounced effects and associations were apparent for Aβ, Tau, and pTau levels from
CSF, while considering cognitively normal participants who are APOE ε4-carriers and
KL-VSHET+. These findings suggest that the cognitively normal participants group, aged 60 to
80 years, mainly drove the outcome in our analyses, further strengthening the existing hypothesis that KL-VS heterozygous genotype is favorable for better health and cognition in older
people [18, 53, 58]. Importantly, we also observed that associations between KL heterozygous
cognitively normal participants and different AD endophenotypes are robust to uneven sample size of APOE ε4-carriers and non-carriers as well as differences in the sex and age of the
participants (S6 Table in S2 File). Although, the observed findings appear consistent with our
initial hypothesis and confirm existing literature [6, 42], the detected associations are nominally significant and would likely fail multiple test correction due to limited sample size.
Therefore, additional studies are required to investigate the associations between KL-VSHET+
and AD endophenotypes with relatively larger sample size to draw definitive conclusions.
The exact mechanism underlying the KL-VSHET+ interaction with APOE ε4 and modulation of Aβ, Tau, and pTau burden is yet unknown. However, it is logical to postulate that
KL-VSHET+ may confer resilience by increasing the serum level of circulating Klotho protein
[18, 21] or by changing its function. In animal mouse models, elevated klotho levels have led
to an extended lifespan [17], enhanced cognition [19] and increased resilience to AD-related
toxicity [58]. Other studies in humans indicated that KL-VSHET+ status has protective effects
against brain aging and cognitive decline [21, 59], suggestive of its protective association
against AD. Our findings also suggest that middle-aged APOE ε4-carriers who are KL-VSHET+
might show resilience to age-induced cognitive and tau changes. Interestingly, we have
observed an age-specific association between KL-VSHET+ and AD endophenotypes, which is in
line with existing studies reporting a specific time window for the effect of KL-VS polymorphism [20, 59].
To conclude, our work contributes to the existing literature by demonstrating that the protective effects of KL-VSHET+ extend to AD-related Aβ, Tau, and pTau endophenotypes and
deficits in memory and executive function in cognitively normal APOE ε4-carriers who are at
risk for developing AD. One promising research avenue for the future studies could be to
assess whether Klotho protein levels in the CSF or serum/plasma of participants associate with
measures of preclinical and symptomatic AD.
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Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, et al. Determining cut-points for
Alzheimer’s disease biomarkers: statistical issues, methods and challenges. Biomark Med. 2012.
https://doi.org/10.2217/bmm.12.49 PMID: 22917141

36.

Guvakova MA. Improving patient classification and biomarker assessment using Gaussian Mixture
Models and Bayes’ rule. Oncoscience. 2019. https://doi.org/10.18632/oncoscience.494 PMID:
31984216

37.

Ingber AP, Hassenstab J, Fagan AM, Benzinger TLS, Grant EA, Holtzman DM, et al. Cerebrospinal
Fluid Biomarkers and Reserve Variables as Predictors of Future “Non-Cognitive” Outcomes of Alzheimer’s Disease. J Alzheimer’s Dis. 2016. https://doi.org/10.3233/JAD-150478 PMID: 27104893

38.

Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising
to the challenge of larger and richer datasets. Gigascience. 2015. https://doi.org/10.1186/s13742-0150047-8 PMID: 25722852

39.

Delaneau O, Marchini J, McVeanh GA, Donnelly P, Lunter G, Marchini JL, et al. Integrating sequence
and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat Commun.
2014. https://doi.org/10.1038/ncomms4934 PMID: 25653097

40.

Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012. https://doi.org/10.1038/
ng.2354 PMID: 22820512

41.

Team RC. R core team (2014). R A Lang Environ Stat Comput R Found Stat Comput Vienna, Austria
URL http://www.R-project.org. 2014.

42.

Lo MT, Kauppi K, Fan CC, Sanyal N, Reas ET, Sundar VS, et al. Identification of genetic heterogeneity
of Alzheimer’s disease across age. Neurobiol Aging. 2019. https://doi.org/10.1016/j.neurobiolaging.
2019.02.022 PMID: 30979435

43.
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